)
Revvity (RVTY) investor relations material
Revvity Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Long-range plan and 2027 outlook
Long-range plan reiterated: market growth assumption of 4%-6%, with core growth 200 bps above market, or 6%-8%; segment mix shifted modestly toward life sciences software and reproductive health, with immunodiagnostics slightly lower.
Plan excludes potential AI upside and any impact from capital deployment; 2027 assumptions expected to be further refined over the next 8-10 weeks, with specifics targeted for the 4Q call.
AI, software and research platforms
2026 is expected to bring the largest number of software NPIs to date, including BioDesign, Signals AI, LabGistics and Xynthetica; AI-native development has shortened software release cycles from 18-36 months to months.
LabGistics is an AI-native workflow on the Signals platform, designed to bring drug discovery and development workflows together and support LLMs and AI agents; features are being launched in stages.
Signals is used by more than 1 million users and 46 of the top 50 pharma/biotech customers; SaaS is 30%-35% of the business and expected to double over the next few years to 60%-70%.
APV and net retention rate continue to grow double digits; annual trends are key indicators as organic revenue fluctuates with order renewals.
Pharma/biotech orders include larger instrument purchases, while public institutions building datasets and companies developing LLMs and outsourcing work to CROs are emerging customer groups.
Reagents, instruments and biopharma demand
Reagents remained resilient through the downturn; instrument orders are outpacing revenue, with reagent demand expected to benefit as installed instruments are tested and validated.
Reagent differentiation includes 24-hour delivery for 95% of orders, research engagement and quality; validated research-reagent programs can remain in place for multiple years, including emerging GLP-1 work.
Cellular analysis has a particularly strong backlog; pharma/biotech recovery and AI-driven validation needs are supporting demand, with reagent pull-through typically starting 2-3 quarters after instrument installation.
Instrument demand broadened across cellular analysis and other platforms; in vivo imaging interest is improving, while sample preparation remained soft.
Biopharma growth shifted from discussions to orders, led by pharma and visible first in capital spending; early-stage biotech showed initial signs of recovery but remained a small portfolio segment.
- Targets pair 6%-8% organic growth with 75 bps annual margin expansion and double-digit EPS growth.RVTY
Investor Day 2026 - Q3 pro forma organic growth reached 7%, lifting FY26 guidance to ~5%.RVTY
Q3 2026 - Transformation and AI-driven growth position the business for strong margins and recurring revenue.RVTY
Morgan Stanley 24th Annual Global Healthcare Conference - Diagnostics and life sciences growth, AI-driven innovation, and strong backlog fuel positive outlook.RVTY
2026 Global Healthcare Conference - AI-driven demand and portfolio expansion fuel growth, with margins and SaaS adoption on the rise.RVTY
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 saw strong growth, margin expansion, and raised outlook, led by Diagnostics strength.RVTY
Q2 2026 - Life sciences and software growth accelerate as pharma biotech recovers and AI adoption expands.RVTY
Citi Annual Global Healthcare Conference 2025 - Targeting 6%-8% organic growth and margin expansion through innovation and operational synergies.RVTY
Investor Day 2024 - Q3 revenue up 2% to $684M, adjusted EPS $1.28, and new $1B share repurchase program.RVTY
Q3 2024
)
)
)
)
)
)
)
)